Immuno oncology News and Research

RSS

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

ESMO honors 2020 recipients for advancing the field of oncology

The global coronavirus pandemic has disrupted cancer research, prevention and treatment to an extent never seen before. To sustain the development of medical knowledge and therapeutic progress for patients worldwide, particular attention must now be paid to the future of the discipline - and to the individuals who continue to work tirelessly to make it evolve.

4 Dec 2020

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.

1 Dec 2020

Reprogramming T cells into highly active 'super immune cells' can improve immunotherapy benefits

Immune-system T cells have been reprogrammed into regenerative stem cell-like memory (TSCM) cells that are long-lived, highly active "super immune cells" with strong antitumor activity, according to new research from Georgetown Lombardi Comprehensive Cancer Center.

23 Nov 2020

New study may shed light on the adaptive immune response to COVID-19

New research funded by the National Cancer Institute (NCI) aims to boost understanding of how the immune system responds to COVID-19, from the start of infection to recovery.

18 Nov 2020

Researchers identify new prognostic markers for colon cancer

The gut-associated lymphoid tissue represents an integral part of the immune system. Among the powerful players of the mucosa-associated lymphoid tissue are isolated lymphoid structures (ILSs).

11 Nov 2020

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

5 Oct 2020

Study shows huge asymmetry in cancer clinical trials in different countries

Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020.

18 Sep 2020

UofL receives $11.5 million to accelerate the development of new immunotherapies

Cancer remains one of the most difficult and deadly challenges in human health, affecting Kentuckians at a higher rate than residents of any other state and killing more than 600,000 people each year in the U.S. alone.

14 Sep 2020

Monash University researchers pave way for affordable immunotherapies

Researchers from Monash University’s Institute of Pharmaceutical Sciences are paving the way for accessible and affordable cancer treatment by using powerful nanoscale tools to overcome the high costs and long lead-times associated with one of the world’s newest forms of immunotherapy: CAR-T cell therapy.

22 Jul 2020

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.

16 Jul 2020

Ashion's GEM ExTra assay receives Medicare coverage

Ashion Analytics LLC announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, GEM ExTra®, one of the nation's most comprehensive genomic cancer analysis tests.

15 Jul 2020

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

14 Jul 2020

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

9 Jul 2020

PRMT5 inhibitors can help treat advanced melanoma

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

9 Jul 2020

BIA Separations launches novel PrimaS ligand technology to facilitate development of advanced therapies

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction of its novel PrimaS ligand technology.

17 Jun 2020

Texas Heart Institute and 7 Hills Pharma receive $1.9 million to improve stem cell transplants

The Texas Heart Institute and 7 Hills Pharma received a $1.9 million, Phase II STTR (R42) grant from the National Heart Lung Blood Institute to advance further their lead product 7HP349, a novel integrin activator, to define the optimal dosing schedule for cord blood transplant along with a focus on development and production of a formulation that meets safety standards for filing an IND application with the FDA.

12 Jun 2020

Immuno oncology News and Research

Combination therapy places no greater burden on early-stage breast cancer patients

ESMO honors 2020 recipients for advancing the field of oncology

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

Reprogramming T cells into highly active 'super immune cells' can improve immunotherapy benefits

New study may shed light on the adaptive immune response to COVID-19

Researchers identify new prognostic markers for colon cancer

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Study shows huge asymmetry in cancer clinical trials in different countries

UofL receives $11.5 million to accelerate the development of new immunotherapies

Monash University researchers pave way for affordable immunotherapies

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Ashion's GEM ExTra assay receives Medicare coverage

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

PRMT5 inhibitors can help treat advanced melanoma

BIA Separations launches novel PrimaS ligand technology to facilitate development of advanced therapies

Texas Heart Institute and 7 Hills Pharma receive $1.9 million to improve stem cell transplants

Promega announces CE marking for OncoMate MSI Dx Analysis System in Europe

Immuno-oncology may accelerate the development of treatments for COVID-19

Bioinsider presents "Diagnostic Landscape For COVID19” virtual meeting

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News